Efavirenz is a human immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor. The mechanism of action of efavirenz is as a non-nucleoside reverse transcriptase inhibitor, cytochrome p450 3a inducer, cytochrome p450 2b6 inducer, cytochrome p450 2c9 inhibitor, cytochrome p450 2c19 inhibitor, and cytochrome p450 3a4 inhibitor. The chemical classification of efavirenz is non-nucleoside analog.
Efavirenz is a synthetic non-nucleoside reverse transcriptase (rt) inhibitor with antiviral activity. Efavirenz binds directly to the human immunodeficiency virus type 1 (hiv-1) rt, an rna-dependent dna polymerase, blocking its function in viral dna replication. In combination with other antiretroviral drugs, this agent has been shown to significantly reduce hiv viral load, retarding or preventing damage to the immune system and reducing the risk of developing aids. Efavirenz induces activity of the cytochrome p450 system, accelerating its own metabolism.

Efavirenz is a human immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor. The mechanism of action of efavirenz is as a non-nucleoside reverse transcriptase inhibitor, cytochrome p450 3a inducer, cytochrome p450 2b6 inducer, cytochrome p450 2c9 inhibitor, cytochrome p450 2c19 inhibitor, and cytochrome p450 3a4 inhibitor. The chemical classification of efavirenz is non-nucleoside analog.
Efavirenz is a synthetic non-nucleoside reverse transcriptase (rt) inhibitor with antiviral activity. Efavirenz binds directly to the human immunodeficiency virus type 1 (hiv-1) rt, an rna-dependent dna polymerase, blocking its function in viral dna replication. In combination with other antiretroviral drugs, this agent has been shown to significantly reduce hiv viral load, retarding or preventing damage to the immune system and reducing the risk of developing aids. Efavirenz induces activity of the cytochrome p450 system, accelerating its own metabolism.